Sera Prognostics (NASDAQ:SERA – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.
Institutional and Insider Ownership
54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Sera Prognostics and Genmab A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -34,866.67% | -52.54% | -36.97% |
| Genmab A/S | 16.97% | 13.67% | 6.42% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 949.51 | -$31.93 million | ($0.67) | -2.85 |
| Genmab A/S | $4.30 billion | 7.40 | $963.00 million | $1.17 | 43.56 |
Genmab A/S has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Sera Prognostics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Sera Prognostics and Genmab A/S, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Genmab A/S | 0 | 1 | 10 | 1 | 3.00 |
Sera Prognostics currently has a consensus target price of $5.50, suggesting a potential upside of 187.96%. Genmab A/S has a consensus target price of $53.50, suggesting a potential upside of 4.96%. Given Sera Prognostics’ higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Genmab A/S.
Summary
Genmab A/S beats Sera Prognostics on 9 of the 14 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc. is a women’s health company focused on identifying pregnancy risks through blood-based testing and biomarker research. The company develops diagnostic products intended to help healthcare providers assess pregnancy outcomes and support individualized care. Its lead product, the PreTRM test, analyzes proteins in a pregnant patient’s blood to estimate the risk of spontaneous preterm birth. The company has developed the test for use by healthcare providers in the United States and continues to study its potential role in pregnancy care.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
